Natera
A growing volume of preclinical data linking dysbiosis to unfavorable solid organ transplant outcomes such as graft rejection is fueling calls for more rigorous research.
Executives also provided additional information on the firm's Q4 2024 financial performance.
Preliminary Earnings Roundup: Natera, Guardant Health, Exact Sciences, CareDx, GeneDx, More
Several molecular diagnostics firms reported fourth quarter and full-year 2024 revenues and other business updates ahead of the annual JP Morgan Healthcare Conference this week.
GenomeWeb Top 40 Drops 3 Percent in 2024, Reflecting Larger Life Science Struggles in Stock Market
The Dow Jones Industrial Average rose 13 percent year over year, and the Nasdaq rose 29 percent, but the Nasdaq Biotech Index declined 1 percent.
In Brief This Week: Natera, Enzo Biochem, Tempus, Vizgen, Complete Genomics, Parse Biosciences, More
News items for the week of Dec. 16, 2024.